BR0005039A - Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca - Google Patents

Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca

Info

Publication number
BR0005039A
BR0005039A BR0005039-3A BR0005039A BR0005039A BR 0005039 A BR0005039 A BR 0005039A BR 0005039 A BR0005039 A BR 0005039A BR 0005039 A BR0005039 A BR 0005039A
Authority
BR
Brazil
Prior art keywords
eletriptan
migraine
receptor
treatment
antagonists
Prior art date
Application number
BR0005039-3A
Other languages
English (en)
Inventor
Susan Beth Sobolov-Jaynes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0005039A publication Critical patent/BR0005039A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"ANTAGONISTAS DO RECEPTOR NK-1 E ELETRIPTANO PARA O TRATAMENTO DA ENXAQUECA". A presente invenção refere-se a um método de tratar a enxaqueca em um mamífero, incluindo em um ser humano, através da administração ao mamífero de eletriptano ou de um sal farmaceuticamente aceitável de eletriptano e de um antagonista do receptor NK-1 (por exemplo, um antagonista do receptor de substância P). A presente invenção refere-se também com formulações farmacêuticas contendo um veículo farmaceuticamente aceitável, eletriptano ou um sal farmaceuticamente aceitável de eletriptano e um antagonista do receptor NK-1.
BR0005039-3A 1999-10-25 2000-10-25 Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca BR0005039A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16128499P 1999-10-25 1999-10-25
US16489699P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
BR0005039A true BR0005039A (pt) 2003-04-15

Family

ID=26857690

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0005039-3A BR0005039A (pt) 1999-10-25 2000-10-25 Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca

Country Status (4)

Country Link
EP (1) EP1095655A3 (pt)
JP (1) JP2001172178A (pt)
BR (1) BR0005039A (pt)
CA (1) CA2324116A1 (pt)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
ES2063507T3 (es) * 1990-06-01 1995-01-01 Pfizer 3-amino-2-aril-quinuclidinas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ATE116317T1 (de) * 1990-07-23 1995-01-15 Pfizer Chinuclidinderivate.
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
WO1992015585A1 (en) * 1991-03-01 1992-09-17 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-amine derivatives
PL171379B1 (en) * 1991-05-31 1997-04-30 Pfizer Method of obtaining novel derivatives of quinuclidine
DE9290083U1 (de) * 1991-06-20 1994-02-17 Pfizer Inc., New York, N.Y. Fluoralkoxybenzylamino-Derivate von stickstoffhaltigen Heterocyclen
TW202432B (pt) * 1991-06-21 1993-03-21 Pfizer
WO1993006099A1 (en) * 1991-09-16 1993-04-01 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
ATE194340T1 (de) * 1992-12-10 2000-07-15 Pfizer Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
DE69318854T2 (de) * 1993-03-04 1998-10-08 Pfizer Spiroazacyclischderivate als substanz p antagonisten
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
DE69612003T2 (de) * 1995-07-07 2001-06-21 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists

Also Published As

Publication number Publication date
CA2324116A1 (en) 2001-04-25
EP1095655A2 (en) 2001-05-02
EP1095655A3 (en) 2003-03-26
JP2001172178A (ja) 2001-06-26

Similar Documents

Publication Publication Date Title
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
BG105534A (en) 5ht1 means and method for the treatment of migraine
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DE69307340D1 (de) Chinuclidin derivat als substanz p antagonist
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
YU2494A (sh) Farmaceutska formulacija za tretiranje zavisnosti od nikotina
BR9407748A (pt) Formulação farmacéutica processo para preparação da mesma e processo para a prevenção e/ou o tratamento de neurodegeneração ou para a obtenção de um efeito anti-convulsivo ou sedação em um paciente
BG106221A (en) Morphine-containing intranasal pharmaceutical preparations and methods for their administration
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
BR0104345A (pt) Tratamento combinado para a depressão e ansiedade
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
BR0005039A (pt) Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca
SE9502219D0 (sv) Novel medical use
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
BR9810331A (pt) Sal de adição de ácido maléico de 2-etil-5-(1-metil-1,2,5,6-tetraidro-3-piridil-2h-tetrazol ; composições farmacêuticas contendo o referido sal; método para sua preparação e a utilização do mesmo em tratamento de doenças

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTA A 6A, 7A 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.